Gallbladder Carcinoma — Trials

Gallbladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

56 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 18
Recruiting: 8
Ph III recruiting: 1
Growth YoY: —
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05194072	A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors	terminated	Phase 1	250	Seagen, a wholly owned subsidiary of PfizerINDUSTRY	5	Jan 9, 2026	clinicaltrials
NCT03267940	Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma	terminated	Phase 1	85	Halozyme TherapeuticsINDUSTRY